Mood Disorder R&D, Lacking Innovation, Turns to Psychedelics
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward... Read More
Stacy Lawrence has been writing and editing about the business of emerging technologies for almost 20 years. Most recently, she was editor-in-chief of FierceBiotech, where she covered biotech and medtech. She’s also held spots as the biopharma business bureau editor with Elsevier and the finance columnist with biotechnology industry publication BioCentury. Stacy has contributed to publications including Nature Biotechnology, San Francisco Business Times, New Scientist, MIT Technology Review, Business 2.0, and Wired.